Die Forschung über das menschliche Mikrobiom von PrecisionBiotics ist weltweit anerkannt. Unsere Forschung und die unserer Partner wurde in führenden wissenschaftlichen Zeitschriften auf der ganzen Welt veröffentlicht.
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley E. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51. Cited by 1319 other research publications.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. Cited by 723 other research publications.
Brenner DM, Chey WD. Bifidobacterium infantis 35624: A novel probiotic for the treatment of IBS. Rev Gastroenterol Disord. 2009;9(1):7-15. Review.
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-49. Cited by 278.
Konieczna P, Groeger D, Ziegler M, Frei, R, Ferstl R, Shanahan F, Quigley EM, Kiely B, Akdis CA, O’Mahony L. Bifidobacterium infantis 35624 administration induces Foxp3 T Regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut. 2012;61(3):354-66.
Mayer EA. Clinical practice. Irritable bowel syndrome.N Engl J Med. 2008 Apr 17;358(16):1692-9. Cited by 192.
Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325-39.
Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016; 1;6(11):e939.
2016
Allen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016; 1;6(11):e939.
Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-Perez N, Ziegler M, Grant R, Moriarty TF, Plattner S, Healy S, O’Connell Motherway M, Akdis CA, Roper J, Altmann F, van Sinderen D, O’Mahony L. The surface associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host pro-inflammatory responses and in repressing local TH17 responses. Appl Environ Microbiol. 2016 Oct 7. pii: AEM.02238-16.
Hoy-Schulz YE, Jannat K, Roberts T, Zaidi SH, Unicomb L, Luby S, Parsonnet J. Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial. BMC Complement Altern Med. 2016; 16:44.
Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E, Plattner S, Schiavi E, Gleinser M, Groeger D, Grant R, Rodriguez Perez N, Healy S, Svehla E, Windwarder M, Hofinger A, O’Connell Motherway M, Akdis CA, Xu J, Roper J, van Sinderen D, O’Mahony L. Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™. PLoS One. 2016; 11(9):e0162983.
2014
Lomasney
2013
Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium
Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium
Konieczna P, Ferstl R, Ziegler M, Frei R, Nehrbass D, Lauener RP, Akdis CA, O’Mahony L. Immunomodulation by Bifidobacterium
Scully P, Macsharry J, O’Mahony D, Lyons A, O’Brien F, Murphy S, Shanahan F, O’Mahony L. Bifidobacterium
2012
Konieczna P, Akdis CA, Quigley EMM, Shanahan F, O’Mahony. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012;3(3): 261-266.
Konieczna P, Groeger D, Ziegler M, Frei, R, Ferstl R, Shanahan F, Quigley EM, Kiely B, Akdis CA, O’Mahony L. Bifidobacterium
Quigley E, Catanzaro D, Wycherley C, Tillisch K. Tolerability and safety of the probiotic Bifidobacterium
Symonds EL, O’Mahony C, Lapthorne S, O’Mahony D, Mac Sharry J, O’Mahony L, Shanahan F. Bifidobacterium
2011
Catanzaro D, Quigley E, Wycherley C, Tillisch K. Tolerability and safety of the probiotic Bifidobacterium
Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distension. Clin Exp Rheumatol. 2011;29(2 Suppl
Gad M, Ravn P, Søborg DA, Lund-Jensen K, Ouwehand AC, Jensen SS. Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. FEMS Immunol Med Microbiol. 2011;63(1):93-107.
Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of Bifidobacterium
Quigley E, Groeger D, O’Mahony L, Bourke J, Scully P, Dinan T, Shanahan F, Kiely B. Oral administration of the probiotic Bifidobacterium
2010
Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium
McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium
2009
Abeln S, McCarthy N. Probiotic benefits demonstrated in a clinical setting translate to meaningful benefits in the real world:
Brenner DM, Chey WD. Bifidobacterium
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104(4):1033-49
Davies JM, Sheil B, Shanahan F. Bacterial
Sibartie S, O’Hara AM, Ryan J, Fanning A, O’Mahony J, O’Neill S, Sheil B, O’Mahony L, Shanahan F. Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunol. 2009;10:54.
Wall R, Ross RP, Shanahan F, O’Mahony L, Kiely B, Quigley E, Dinan TG, Fitzgerald G, Stanton C. Impact of administered Bifidobacterium on murine host fatty acid composition. Lipids. 2010;45(5):429-36.
2008
Desbonnet L, Garrett L, Clarke G, Bienenstock J, Dinan TG. The probiotic Bifidobacteria
Mayer EA. Clinical practice. Irritable bowel syndrome.N Engl J Med. 2008 Apr 17;358(16):1692-9.
O’Mahony C, Scully P, O’Mahony D, Murphy S, O’Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O’Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4(8):e1000112.
van der Kleij H, O’Mahony C, Shanahan F, O’Mahony L, Bienenstock J. Protective effects of Lactobacillus
2007
Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137(3 Suppl 2):819S-24S.
Shilling D, Coffey C, Smith M, Kavanagh E, Kirwan W, Redmond H, Shanahan F, O’Mahony
Symonds EL, O’Mahony C, O’Mahony D, O’Mahony L, Shanahan F. Probiotic prevention of digestive enzyme damage in a mouse model of Salmonella.Gastroenterology. 2007;132(4 Suppl
2006
Charbonneau D, Poehner R, Donovan-Brand R, Xu J, Fawcett D. Development of
Gilman J, Cashman KD. The effect of probiotic bacteria on transepithelial calcium transport and calcium uptake in human intestinal-like Caco-2 cells.Curr Issues Intest Microbiol. 2006;7(1):1-5.
O’Hara AM, O’Regan P, Fanning A, O’Mahony C, MacSharry J, Lyons A, Bienenstock J, O’Mahony L, Shanahan F. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium
O’Mahony L, O’Callaghan L, McCarthy J, Shilling D, Scully P, Sibartie S, Kavanagh E, Kirwan WO, Redmond HP, Collins JK, Shanahan F. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol. 2006;290(
Quigley EM, Whorwell PJ, Shanahan F, Vansinderen D, Xu J, Altringer L, O’Mahony L, Guarner F, Progid Investigators. Safety and tolerability of the probiotic organism Bifidobacterium
Shanahan F, Guarner F, Von Wright A, Vilpponen-Salmela T, O’Donoghue D, Kiely B, Progid Investigators. A one year, randomised, double-blind,
Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F. Consumption of the
Sheil B, MacSharry J, O’Callaghan L, O’Riordan A, Waters A, Morgan J, Collins JK, O’Mahony L, Shanahan F. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin Exp Immunol. 2006;144(2):273-80.
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated
2005
Bairead E, O’Mahony L, MacSharry J, Scully P, Fanning A, Kiely B, O’Mahony S, Shanahan F, Quigley E. Alterations in immunological gene expression from colonic biopsies of female IBS patients following probiotic consumption. Gastroenterology, 2005, 128 (44).
Chang K, Fangyi L, Hendrix S, Altringer L, Charbonneau D, Poehner R, Carryl O, Trowbridge M, O’Mahony L, Quigley E, Shanahan F S. Modulation of cytokine profiles in healthy and IBS subjects following supplementation with the unique probiotic strain, Bifidobacterium
Charbonneau D, Baria M, Poehner R, Mccauley-Myers D, Eads C, Furnish C, Donovan-Brand R. Impact of Bifidobacterium
Charbonneau DL, Altringer LA, Carryl OR, Chen K-S, Kidd KJ, Darcy T, Fawcett DH, Trowbridge M M, Jang C, Luo F, Poehner RD, Meller ST. Fecal flora effects following oral supplementation with Bifidobacteria
Chen K-S, Luo F, Hendrix SW, Altringer LA, Charbonneau DL, Poehner RD, Carryl OR, Trowbridge MM, O’Mahony L, Shanahan F, Quigley E, Meller
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley E. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-51.
O’Mahony L, Sheil B, Murphy C, Duke K, Murphy S, Kiely B, Shanahan F. Bifidobacterial induced cytokine production in vitro as predictive biomarkers
Quigley EM, Whorwell PJ, Altringer L, Morel J, O’Mahony L, Shanahan F. Probiotic use results in normalization of bowel movement frequency in IBS. Results from a clinical trial with the novel probiotic Bifidobacteria
Quigley EM, Whorwell PJ, Altringer L, Morel J, O’Mahony L, Shanahan F. Who is the responder to probiotic therapy in IBS? Data from a controlled clinical trial with Bifidobacterium
Sommerfield D, MacSharry J, O’Mahony D, O’Mahony L, Kiely B, Shanahan F, Quigley EM Effect of probiotic feeding on Salmonella translocation in a Mouse model. Gastroenterology. 2005;
2004
O’Callaghan L, Sheil B, MacSharry J, Collins J, O’Mahony L, Shanahan F. Cytokine responses in different lymphoid compartments in IL-10/ko mice fedBifidobacterium
O’Mahony L, Shiel B, MacSharry, O’Callaghan L, Collins J, O’Sullivan G, Kiely B, Shanahan F. Mechanism of probiotic/commensal mediated protection against invasive Salmonella infection. Gastroenterology. 2004;126:A516 (Abstract T1809).
2003
MacConaill LE, Butler D, O’Connell-Motherway M, Fitzgerald GF, van Sinderen D. Identification of two-component regulatory systems in Bifidobacteriuminfantis by functional complementation and degenerate PCR approaches. Appl Environ Microbiol. 2003;69(7):4219-26.
McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan E, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, Shanahan F.
O’Callaghan L, O’Mahony L, McCarthy J, Kavanaugh E, Kirwan W, Redmond P, Shanahan F, Collins J. Differential cytokine response of cells derived from different lymphoid compartments to commensal and pathogenic bacteria. Gastroenterology. 2003;124:A339 (Abstract M1253).
O’Regan P, Powers A, MacSharry J, O’Sullivan G, Kiely B, Collins J, O’Mahony L, Shanahan F. Plasticity of epithelial cell cytokine responses to commensal and pathogenic species. Gastroenterology. 2003;
Sommerfield D, O’Brien N, Kiely B, Collins J, Shanahan F, O’Mahony L, Quigley E. Influence of Bifidobacterium
2002
O’Callaghan L, O’Mahony L, O’Mahony K, Kavanaugh E, Kirwan W, Collins J, Shanahan F. Human cytokine production by mesenteric lymph node cells in response to probiotic and pathogenic bacteria. Gastroenterology. 2002;122:A151 (Abstract S1040).
O’Mahony L, Kenneally P, O’Donoghue M, Kiely B, Shanahan F, Collins J. Multi-organism comparison of probiotic performance in a murine model ofSalmonella
Sheil B, O’Mahony L, O’Callaghan L, Collins J, Shanahan F. Variability in human cytokine responses to different Lactobacilli and Bifidobacteria.Gastroenterology. 2002;122:A281 (Abstract M1161).
von Wright A, Vilpponen-Salmela T, Llopis MP, Collins K, Kiely B, Shanahan F, Dunne C. The survival and colonic adhesion of Bifidobacterium
2001
O’Mahony L, Zong Z, Sharma S, Aranda R, O’Sullivan G, Collins JK, Shanahan F. Probiotic bacteria and pathogenic bacteria elicit differential cytokine responses from dendritic cells. Gastroenterology. 2001;120:A315 (Abstract 1625).
2000
O’Mahony L, Dunne C, Feeney M, O’Halloran S, Kiely B, O’Sullivan GC, Shanahan FL, Collin JK. Probiotic human Bifidobacteria selection of a new strain and evaluation in vitro and in vivo. Gastroenterology. 2000;118(4
1999
Dunne C, Murphy L, Flynn S, O’Mahony L, O’Halloran S, Feeney M, Morrissey D, Thornton G, Fitzgerald G, Daly C, Kiely B, Quigley EM, O’Sullivan G, Shanahan F, Collins JK. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 1999; 76(1-4):279-92. Review.
“Since taking Alflorex, my symptoms have cleared up and I feel I’ve got control again over my bowel. I’m eating whatever I like and I’m getting through stressful events without flare ups.”
Jen, 22
Munster
Gary
30, Galway
Jon, 36
Dublin
The Careline team
Our Careline team is here to answer any questions you have
We welcome questions from the public and healthcare professionals
If you have a question, please call us on
UK: 0330 057 8598
Ireland: 021 206 6012
Or email us by filling out the form on the right.
Thank you
Building 4400,
Cork Airport Business Park,
Kinsale Road,
Cork T12 N84F,
Ireland.
Telefonnummer:
IRL: 021 206 6012
Email:
ask@precisionbiotics.com
Wir sind ein Unternehmen, dessen Hauptziel es ist, die besten "freundlichen" Bakterien und Probiotika der Natur zu nutzen, um Verbrauchern und Ärzten auf der ganzen Welt zu unterstützen. Wir sind stolz auf unseren Forschungserfolg und unsere Partnerschaft mit einem der weltweit führenden Zentren für Mikrofloraforschung, um weltweit führende Probiotika zu testen und zu entwickeln.